A Long-Term Follow-Up Study of Participants Exposed to REACT
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-80
SponsorProkidney
About this trial
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Eligibility criteria
Qualifiers
The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
Disqualifiers
The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.
Trial design
Treatments tested in this trial
- Renal Autologous Cell Therapy (REACT)
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov